Bio*One Capital's A-Bio Pharma Secures A Second Deal With GlaxoSmithKline
$9 million Expansion of Facility Underway
Bio*One Capital Pte Ltd, a leading biomedical sciences investment management company, announced that its portfolio company A-Bio Pharma Pte Ltd (A-Bio), has clinched its second process development and clinical supply service agreement with GlaxoSmithKline Biologicals (GSK Bio) via the signing of an agreement with Glaxo Wellcome Manufacturing Pte Ltd. Under the contract, A-Bio will work closely with GSK Bio to develop and produce clinical lots for one of its many promising vaccine products at A-Bio's GMP biopharmaceutical facility in Singapore.
This deal follows the first project with GSK Bio that was announced in November 2004 as well as the master service agreement with Novo Nordisk A/S in May 2005.
With the securing of these agreements as well as a few more in the pipeline, there will be a further investment of S$9 million (US$5.5 million) to expand A-Bio's cell culture manufacturing capacity to meet increasing customer demand. A-Bio will add a 500L stirred tank bioreactor to its existing 200L capacity.
Most read news
Organizations
Other news from the department manufacturing

Get the life science industry in your inbox
By submitting this form you agree that LUMITOS AG will send you the newsletter(s) selected above by email. Your data will not be passed on to third parties. Your data will be stored and processed in accordance with our data protection regulations. LUMITOS may contact you by email for the purpose of advertising or market and opinion surveys. You can revoke your consent at any time without giving reasons to LUMITOS AG, Ernst-Augustin-Str. 2, 12489 Berlin, Germany or by e-mail at revoke@lumitos.com with effect for the future. In addition, each email contains a link to unsubscribe from the corresponding newsletter.